Haleon

HLN

Drug Manufacturers - Specialty & Generic · Healthcare

Also trades as: HLN.L

Price

$10.00

+0.13 (+1.32%)

Market Cap

$44.04B

Exchange

New York Stock Exchange

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Good

Growth

Mixed

Cash Flow

Data not available

Stability

Mixed

Valuation

Good

Dividends

Weak

Track this stock — start free trial

Share count falling — buybacks

−2.4% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 4.62B (2021) → 4.51B (2025)

Winston Score History

The full picture

Haleon is a consumer health company that makes everyday health products people buy at pharmacies and grocery stores. Its brands include Sensodyne toothpaste, Advil pain relievers, Centrum vitamins, and Theraflu cold medicine. These products are sold directly to ordinary consumers around the world, making Haleon one of the largest standalone consumer health companies globally.

Haleon makes money by selling its branded products through retailers, pharmacies, and e-commerce channels. It operates in over 100 countries, with strong sales across North America, Europe, and Asia-Pacific, and generates roughly $13 billion in annual revenue. Its main competitive advantage is its portfolio of trusted, recognizable brand names that consumers repeatedly buy out of habit. The key risk is that Haleon carries significant debt from its 2022 spinoff from GSK, and it also faces ongoing legal liability related to Zantac, a heartburn drug previously sold by its predecessor businesses.

Politician Trades

1 trades / 12mo

0 Congressional buys and 1 sell on HLN in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+3.0% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-5.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

£308M/ year

→ Flat (+3% vs prior year)

2.8% of revenue

Below sector average (18%)

Steady R&D investment year-over-year

Insider Activity

0.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

£898M cash & investments

Quarterly Free Cash Flow

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Haleon is growing revenue at 3% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

66.0%

Premium pricing power — 66.0% gross margin

Profit after running costs

Operating Margin

23.8%

Excellent — 23.8% operating margin

Return on the money invested

ROCE

5.5%

Weak — 5.5% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.50

Conservative — low debt load (0.50)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

20.0x

Growth-priced — P/E 20.0

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year

P/E vs Forward

+5.9

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (20.0 → 14.1)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

1.95%

Small dividend — 1.95% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record

Dividend Growth

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial